Probi announces new representative for Blis Board

20 December 2022 Probi announces new representative for Blis Board Blis Technologies Limited (NZX:BLT) advises the appointment of Dr Jorn Andreas as a director of the company with effect from 1 January 2023. Dr Andreas will replace Tom Ronnlund who is retiring from the board following stepping down as CEO of Probi AB earlier this month. Dr Andreas has been a director of Probi AB since 2019 and is CEO of the Cosmetic Ingredients Division at Symrise . He also has experience from both a previous assignment as board member (2014-2016) at Probi and his position as CFO of the company (2017-2018). He has extensive international experience working at Symrise in France and USA in different finance and general management roles. Jorn has also worked for The Boston Consulting Group and Bayer AG in Germany. The board has determined that Dr Andreas is not an independent director due to his role as a director of Probi AB, which is a substantial product holder of Blis Technologies. Dr Andreas will formally offer himself for re-election as director at the 2023 shareholders' meeting. Chairman Geoff Plunket said "We are delighted to have Jorn joining the board. Jorn has extensive commercial experience in senior executive and board roles that will complement our refocused strategy. His experience with both Probi and Symrise provides insight across a significant cross section of ingredient markets globally." I also wish to acknowledge the contribution Tom has made during his time on the board. He has provided valuable insights into the probiotic market and been pivotal in his role as Probi CEO in establishing a strong working relationship between the Blis and Probi teams. Ends For further information, please contact: Geoff Plunket Chair +64 21 229 8886 About Blis Technologies Ltd Delivering proven health benefits through evidence-based, advanced probiotics Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS(R) products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz. End CA:00404433 For:BLT Type:ADMIN Time:2022-12-20 14:43:58